{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:34Z","timestamp":1787032774683,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,28]]},"DOI":"10.7759\/cureus.106043","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T03:36:32Z","timestamp":1774755392000},"source":"Crossref","is-referenced-by-count":1,"title":["Direct Oral Anticoagulants Versus Warfarin in Atrial Fibrillation With Advanced Chronic Kidney Disease: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ali S","family":"Metwaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aymen A","family":"Alqurain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal F","family":"Alghanim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada A","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragad K","family":"Alsudairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aref Y","family":"Dayl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil S","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osaid H","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadel M","family":"Alfaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser Q","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal Y","family":"Alfaifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tala H","family":"Abdulmgid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zainab A","family":"Alkaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.034176","article-title":"Anticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: a systematic review and network meta-analysis","volume":"13","author":"Kao TW","year":"2024","unstructured":"Kao TW, Chen ZW, Lin YH. Anticoagulation for patients with concomitant atrial fibrillation and end-stage renal disease: a systematic review and network meta-analysis. J Am Heart Assoc. 2024, 13:e034176. 10.1161\/JAHA.123.034176","journal-title":"J Am Heart Assoc"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-57460-4_25","article-title":"Anticoagulation for Atrial Fibrillation in Advanced Chronic Kidney Disease","author":"Genovesi S","year":"2021","unstructured":"Genovesi S, Ronco F. Anticoagulation for Atrial Fibrillation in Advanced Chronic Kidney Disease. Textbook of cardiorenal medicine. McCullough PA, Ronco C (ed): Springer International Publishing, 2021. 333-41. 10.1007\/978-3-030-57460-4_25"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.31083\/RCM26736","article-title":"Anticoagulation strategies for atrial fibrillation in CKD stage G5 and dialysis patients: an updated scoping review","volume":"26","author":"de Oliveira HM","year":"2025","unstructured":"de Oliveira HM, Barros LP, de Campos MC, et al.. Anticoagulation strategies for atrial fibrillation in CKD stage G5 and dialysis patients: an updated scoping review. Rev Cardiovasc Med. 2025, 26:26736. 10.31083\/RCM26736","journal-title":"Rev Cardiovasc Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-76419-7_75","article-title":"Coagulation in Kidney Disease","author":"Prasannan N","year":"2022","unstructured":"Prasannan N, Forbes SH, Chowdary P. Coagulation in Kidney Disease. Primer on nephrology. Harber M (ed): Springer International Publishing, 2022. 1253-73. 10.1007\/978-3-030-76419-7_75"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-021-07144-8","article-title":"Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4-5 chronic kidney disease or on dialysis","volume":"35","author":"Chen C","year":"2021","unstructured":"Chen C, Cao Y, Zheng Y, Dong Y, Ma J, Zhu W, Liu C. Effect of rivaroxaban or apixaban in atrial fibrillation patients with stage 4-5 chronic kidney disease or on dialysis. Cardiovasc Drugs Ther. 2021, 35:273-81. 10.1007\/s10557-021-07144-8","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011373.pub2","article-title":"Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease","volume":"11","author":"Kimachi M","year":"2017","unstructured":"Kimachi M, Furukawa TA, Kimachi K, Goto Y, Fukuma S, Fukuhara S. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. Cochrane Database Syst Rev. 2017, 11:CD011373. 10.1002\/14651858.CD011373.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-75326-9_6","article-title":"Atrial Fibrillation","author":"Parikh MG","year":"2022","unstructured":"Parikh MG. Atrial Fibrillation. Cardiac electrophysiology. Springer International Publishing, 2022. 155-81. 10.1007\/978-3-030-75326-9_6"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/joa3.13051","article-title":"Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis","volume":"40","author":"AlTurki A","year":"2024","unstructured":"AlTurki A, Marafi M, Dawas A, et al.. Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis. J Arrhythm. 2024, 40:440-7. 10.1002\/joa3.13051","journal-title":"J Arrhythm"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-025-02711-7","article-title":"Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonists in dialysis patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis","author":"Li T","year":"2025","unstructured":"Li T, Li T, Xu Y, Gjermeni D, Heger L, Westermann D, Olivier CB. Comparing the efficacy and safety of direct oral anticoagulants with vitamin K antagonists in dialysis patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis. Clin Res Cardiol. 2025, 10.1007\/s00392-025-02711-7","journal-title":"Clin Res Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.885548","article-title":"Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis","volume":"9","author":"Rhee TM","year":"2022","unstructured":"Rhee TM, Lee SR, Choi EK, Oh S, Lip GY. Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2022, 9:885548. 10.3389\/fcvm.2022.885548","journal-title":"Front Cardiovasc Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1210560","article-title":"Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation","volume":"14","author":"Armentaro G","year":"2023","unstructured":"Armentaro G, D'Arrigo G, Bo M, et al.. Medium-term and long-term renal function changes with direct oral anticoagulants in elderly patients with atrial fibrillation. Front Pharmacol. 2023, 14:1210560. 10.3389\/fphar.2023.1210560","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-024-01138-5","article-title":"Direct oral anticoagulants in older and frail patients with atrial fibrillation: a decade of experience","volume":"41","author":"Spruit JR","year":"2024","unstructured":"Spruit JR, de Vries TA, Hemels ME, Pisters R, de Groot JR, Jansen RW. Direct oral anticoagulants in older and frail patients with atrial fibrillation: a decade of experience. Drugs Aging. 2024, 41:725-40. 10.1007\/s40266-024-01138-5","journal-title":"Drugs Aging"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.09.005","article-title":"Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies","volume":"231","author":"Zagoridis K","year":"2023","unstructured":"Zagoridis K, Karatisidis L, Mprotsis T, Pentidou A, Bezirgianidou Z, Misidou C, Spanoudakis E. Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies. Thromb Res. 2023, 231:17-24. 10.1016\/j.thromres.2023.09.005","journal-title":"Thromb Res"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2026.103398","article-title":"Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis","volume":"10","author":"Almajdi A","year":"2026","unstructured":"Almajdi A, Almutairi S, Alharbi M. Safety and efficacy of rivaroxaban versus warfarin in atrial fibrillation with stage 4 to 5 chronic kidney disease including dialysis. Res Pract Thromb Haemost. 2026, 10:103398. 10.1016\/j.rpth.2026.103398","journal-title":"Res Pract Thromb Haemost"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1320939","article-title":"Anticoagulant drugs for patients with atrial fibrillation on dialysis: a systematic analysis and network meta-analysis","volume":"14","author":"Shen XF","year":"2023","unstructured":"Shen XF, Zhang C, Hu J, Zhang T, Ma B. Anticoagulant drugs for patients with atrial fibrillation on dialysis: a systematic analysis and network meta-analysis. Front Pharmacol. 2023, 14:1320939. 10.3389\/fphar.2023.1320939","journal-title":"Front Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2023.08.116","article-title":"Safety and efficacy of direct oral anticoagulants versus warfarin for atrial fibrillation in end-stage renal disease on hemodialysis: a meta-analysis of randomized control trials","volume":"206","author":"Faisaluddin M","year":"2023","unstructured":"Faisaluddin M, Alwifati N, Naeem N, Balasubramanian S, Narasimhan B, Iqbal U, Dani SS. Safety and efficacy of direct oral anticoagulants versus warfarin for atrial fibrillation in end-stage renal disease on hemodialysis: a meta-analysis of randomized control trials. Am J Cardiol. 2023, 206:309-11. 10.1016\/j.amjcard.2023.08.116","journal-title":"Am J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2020.09.041","article-title":"Safety and efficacy of apixaban, rivaroxaban, and warfarin in end-stage renal disease with atrial fibrillation: a systematic review and meta-analysis","volume":"30","author":"Abdullah HM","year":"2021","unstructured":"Abdullah HM, Ullah W, Jafar MS, et al.. Safety and efficacy of apixaban, rivaroxaban, and warfarin in end-stage renal disease with atrial fibrillation: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2021, 30:26-32. 10.1016\/j.carrev.2020.09.041","journal-title":"Cardiovasc Revasc Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1177\/10760296241271423","article-title":"Factor Xa inhibitors versus vitamin K antagonists in atrial fibrillation patients with end-stage kidney disease on dialysis: a meta-analysis","volume":"30","author":"Xiong M","year":"2024","unstructured":"Xiong M, Guo L, Wan Y. Factor Xa inhibitors versus vitamin K antagonists in atrial fibrillation patients with end-stage kidney disease on dialysis: a meta-analysis. Clin Appl Thromb Hemost. 2024, 30:10760296241271423. 10.1177\/10760296241271423","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102332","article-title":"Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists","volume":"8","author":"Tscharre M","year":"2024","unstructured":"Tscharre M, Steiner D, Mutschlechner D, Ay C, Gremmel T. Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists. Res Pract Thromb Haemost. 2024, 8:102332. 10.1016\/j.rpth.2024.102332","journal-title":"Res Pract Thromb Haemost"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-023-02945-0","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: a systematic review and meta-analysis of randomized controlled trials","volume":"57","author":"de Lucena LA","year":"2024","unstructured":"de Lucena LA, Freitas MA, Souza AK, et al.. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: a systematic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2024, 57:381-9. 10.1007\/s11239-023-02945-0","journal-title":"J Thromb Thrombolysis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen J","year":"1960","unstructured":"Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960, 20:37-46. 10.1177\/001316446002000104","journal-title":"Educ Psychol Meas"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne JA","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, et al.. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016, 355:i4919. 10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"ref25","unstructured":"R Core Team. R. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. (2026). Accessed: 5\/1\/2026: https:\/\/www.R-project.org\/."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian R","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986, 7:177-88. 10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-8-79","article-title":"Undue reliance on I(2) in assessing heterogeneity may mislead","volume":"8","author":"R\u00fccker G","year":"2008","unstructured":"R\u00fccker G, Schwarzer G, Carpenter JR, Schumacher M. Undue reliance on I(2) in assessing heterogeneity may mislead. BMC Med Res Methodol. 2008, 8:79. 10.1186\/1471-2288-8-79","journal-title":"BMC Med Res Methodol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg CB","year":"1994","unstructured":"Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50:1088-101. 10.2307\/2533446","journal-title":"Biometrics"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-017-0315-7","article-title":"Trial sequential analysis in systematic reviews with meta-analysis","volume":"17","author":"Wetterslev J","year":"2017","unstructured":"Wetterslev J, Jakobsen JC, Gluud C. Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017, 17:39. 10.1186\/s12874-017-0315-7","journal-title":"BMC Med Res Methodol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-020-07108-4","article-title":"Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis: a population-based cohort study and meta-analysis","volume":"35","author":"See LC","year":"2021","unstructured":"See LC, Lee HF, Chao TF, et al.. Effectiveness and safety of direct oral anticoagulants in an Asian population with atrial fibrillation undergoing dialysis: a population-based cohort study and meta-analysis. Cardiovasc Drugs Ther. 2021, 35:975-86. 10.1007\/s10557-020-07108-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.08.017","article-title":"Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study","volume":"83","author":"Fu EL","year":"2024","unstructured":"Fu EL, Desai RJ, Paik JM, et al.. Comparative safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with advanced CKD and atrial fibrillation: nationwide US cohort study. Am J Kidney Dis. 2024, 83:293-305.e1. 10.1053\/j.ajkd.2023.08.017","journal-title":"Am J Kidney Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-023-02859-x","article-title":"Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease","volume":"56","author":"Hsu CC","year":"2023","unstructured":"Hsu CC, Chen CC, Chou CY, Chen KH, Wang SF, Chang SL, Chang YL. Effectiveness and safety of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and advanced kidney disease. J Thromb Thrombolysis. 2023, 56:518-28. 10.1007\/s11239-023-02859-x","journal-title":"J Thromb Thrombolysis"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad004","article-title":"Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D","volume":"16","author":"Welander F","year":"2023","unstructured":"Welander F, Renlund H, Dim\u00e9ny E, Holmberg H, Sj\u00e4lander A. Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D. Clin Kidney J. 2023, 16:835-44. 10.1093\/ckj\/sfad004","journal-title":"Clin Kidney J"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae206","article-title":"Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants","volume":"17","author":"Welander F","year":"2024","unstructured":"Welander F, Renlund H, Sj\u00e4lander A. Risk factors for major bleeding in patients with atrial fibrillation and CKD G3-G5D on oral anticoagulants. Clin Kidney J. 2024, 17:sfae206. 10.1093\/ckj\/sfae206","journal-title":"Clin Kidney J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1177\/1060028018781853","article-title":"Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease","volume":"52","author":"Schafer JH","year":"2018","unstructured":"Schafer JH, Casey AL, Dupre KA, Staubes BA. Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Ann Pharmacother. 2018, 52:1078-84. 10.1177\/1060028018781853","journal-title":"Ann Pharmacother"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease","volume":"223","author":"Weir MR","year":"2020","unstructured":"Weir MR, Ashton V, Moore KT, Shrivastava S, Peterson ED, Ammann EM. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease. Am Heart J. 2020, 223:3-11. 10.1016\/j.ahj.2020.01.010","journal-title":"Am Heart J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial","volume":"146","author":"Pokorney SD","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, et al.. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022, 146:1735-45. 10.1161\/CIRCULATIONAHA.121.054990","journal-title":"Circulation"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study","volume":"147","author":"Reinecke H","year":"2023","unstructured":"Reinecke H, Engelbertz C, Bauersachs R, et al.. A randomized controlled trial comparing apixaban with the vitamin K antagonist phenprocoumon in patients on chronic hemodialysis: the AXADIA-AFNET 8 study. Circulation. 2023, 147:296-309. 10.1161\/CIRCULATIONAHA.122.062779","journal-title":"Circulation"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020111566","article-title":"Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial","volume":"32","author":"De Vriese AS","year":"2021","unstructured":"De Vriese AS, Caluw\u00e9 R, Van Der Meersch H, De Boeck K, De Bacquer D. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol. 2021, 32:1474-83. 10.1681\/ASN.2020111566","journal-title":"J Am Soc Nephrol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.035418","article-title":"Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States","volume":"138","author":"Siontis KC","year":"2018","unstructured":"Siontis KC, Zhang X, Eckard A, et al.. Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States. Circulation. 2018, 138:1519-29. 10.1161\/CIRCULATIONAHA.118.035418","journal-title":"Circulation"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2022.03.007","article-title":"Apixaban dosing patterns versus warfarin in patients with nonvalvular atrial fibrillation receiving dialysis: a\u00a0retrospective cohort study","volume":"80","author":"Wetmore JB","year":"2022","unstructured":"Wetmore JB, Weinhandl ED, Yan H, Reyes JL, Herzog CA, Roetker NS. Apixaban dosing patterns versus warfarin in patients with nonvalvular atrial fibrillation receiving dialysis: a\u00a0retrospective cohort study. Am J Kidney Dis. 2022, 80:569-579.e1. 10.1053\/j.ajkd.2022.03.007","journal-title":"Am J Kidney Dis"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2019.04.013","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis","volume":"132","author":"Coleman CI","year":"2019","unstructured":"Coleman CI, Kreutz R, Sood NA, Bunz TJ, Eriksson D, Meinecke AK, Baker WL. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis. Am J Med. 2019, 132:1078-83. 10.1016\/j.amjmed.2019.04.013","journal-title":"Am J Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014113","article-title":"Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis","volume":"131","author":"Chan KE","year":"2015","unstructured":"Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015, 131:972-9. 10.1161\/CIRCULATIONAHA.114.014113","journal-title":"Circulation"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249940","article-title":"Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study","volume":"16","author":"Lin YC","year":"2021","unstructured":"Lin YC, Chen BL, Shih CM, et al.. Effectiveness and safety of rivaroxaban versus warfarin in Taiwanese patients with end-stage renal disease and nonvalvular atrial fibrillation: a real-world nationwide cohort study. PLoS One. 2021, 16:e0249940. 10.1371\/journal.pone.0249940","journal-title":"PLoS One"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017694654","article-title":"Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease","volume":"51","author":"Sarratt SC","year":"2017","unstructured":"Sarratt SC, Nesbit R, Moye R. Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease. Ann Pharmacother. 2017, 51:445-50. 10.1177\/1060028017694654","journal-title":"Ann Pharmacother"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1905","article-title":"Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment","volume":"37","author":"Stanton BE","year":"2017","unstructured":"Stanton BE, Barasch NS, Tellor KB. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017, 37:412-9. 10.1002\/phar.1905","journal-title":"Pharmacotherapy"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfae042","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis","volume":"39","author":"Laville SM","year":"2024","unstructured":"Laville SM, Couchoud C, Bauwens M, Vacher-Coponat H, Choukroun G, Liabeuf S. Efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients on chronic dialysis. Nephrol Dial Transplant. 2024, 39:1662-71. 10.1093\/ndt\/gfae042","journal-title":"Nephrol Dial Transplant"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2024.102160","article-title":"Reprint of: Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis","volume":"64","author":"Moore M","year":"2024","unstructured":"Moore M, Vizcaino K, Ewing JA, St Ville M. Reprint of: Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis. J Am Pharm Assoc (2003). 2024, 64:102160. 10.1016\/j.japh.2024.102160","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13599","article-title":"Safety of apixaban compared to warfarin in hemodialysis patients: do antiplatelets make a difference?","volume":"106","author":"Ionescu F","year":"2021","unstructured":"Ionescu F, Cooper C, Petrescu I, George J, Mansuri S. Safety of apixaban compared to warfarin in hemodialysis patients: do antiplatelets make a difference?. Eur J Haematol. 2021, 106:689-96. 10.1111\/ejh.13599","journal-title":"Eur J Haematol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044059","article-title":"Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease","volume":"141","author":"Stanifer JW","year":"2020","unstructured":"Stanifer JW, Pokorney SD, Chertow GM, et al.. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020, 141:1384-92. 10.1161\/CIRCULATIONAHA.119.044059","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/476076-direct-oral-anticoagulants-versus-warfarin-in-atrial-fibrillation-with-advanced-chronic-kidney-disease-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T03:36:41Z","timestamp":1774755401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/476076-direct-oral-anticoagulants-versus-warfarin-in-atrial-fibrillation-with-advanced-chronic-kidney-disease-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":53,"URL":"https:\/\/doi.org\/10.7759\/cureus.106043","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}